Biography:Eric Aboagye
Eric Aboagye | |
|---|---|
| Born | Ghana |
| Alma mater | Kwame Nkrumah University of Science and Technology (BSc) University of Strathclyde (MSc) University of Glasgow (PhD) |
| Scientific career | |
| Institutions | Johns Hopkins University Imperial College London |
| Thesis | Fluorinated 2-Nitroimidazoles: Non-Invasive Probes for Detecting Therapeutically Relevant Tumour Hypoxia by Magnetic Resonance Spectroscopy (1995) |
Eric Ofori Aboagye is a Professor of Cancer Pharmacology and Molecular Imaging at Imperial College London. He is a Fellow of the Academy of Medical Sciences and was awarded the British Institute of Radiology Sir Mackenzie Davidson Medal in 2009. He is co-director of the Imperial College London Experimental Cancer Medicine's Centre.
Early life and education
Aboagye was born in Ghana.[1] He studied pharmacy at the Kwame Nkrumah University of Science and Technology in 1989.[1] He moved to the United Kingdom shortly after, and completed a master's degree in pharmaceutical analysis at the University of Strathclyde.[1] He earned his doctoral degree at the Cancer Research UK Beatson Laboratories in Glasgow. He was a postdoctoral researcher at Johns Hopkins University.[2]
Research and career
Aboagye joined Imperial College London as a research associate in 1998.[1] He was promoted to Professor in 2006. He is interested in molecular imaging and the development of novel imaging for cancer diagnosis.[1] He is Director of the Comprehensive Cancer Imaging Centre, which combines synthetic chemistry, software development and biomedical science in an effort to diagnose and treat cancer patients.[3]
He has demonstrated that artificial intelligence is significantly more accurate than blood tests in predicting the survival rates of ovarian cancer.[4] For the study, Aboagye used TexLab to analyse CT scans and establish the health risks associated with different tumours.[4] The software was trained to analyse the shape, size, genetic composition and structure of tumours.[4] Aboagye have developed imaging tools capable of characterising choline, glycogen and fatty acid metabolism.[5]
Awards and honours
His awards and honours include:
- 2009 British Institute of Radiology Sir Mackenzie Davidson Medal[6]
- 2010 Elected Fellow of the Academy of Medical Sciences[3]
Selected publications
His publications include:
- Aboagye, Eric O. (1999). "Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells". Cancer Research 59 (1): 80–4. PMID 9892190. https://cancerres.aacrjournals.org/content/59/1/80.short.
- Aboagye, Eric O. (2013). "Magnetic nanoparticles as contrast agents in the diagnosis and treatment of cancer". Chemical Society Reviews 42 (19): 7816–33. doi:10.1039/C3CS60149H. PMID 23788179.
- Aboagye, Eric O. (2003). "3′-Deoxy-3′-[18FFluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography"]. Cancer Research 63. https://cancerres.aacrjournals.org/content/63/13/3791.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Dr Eric O. Aboagye, PhD FMedSci | Speaker at PMF Cancer 2019" (in en-GB). 2019-10-21. https://precisionmedicineforum.com/eric-o-aboagye/.
- ↑ "Eric Aboagye: Scientific Director, ECMC". https://crukimperialcentre.co.uk/about-us/eric-aboagye/.
- ↑ 3.0 3.1 "Professor Eric Aboagye | The Academy of Medical Sciences". https://acmedsci.ac.uk/fellows/fellows-directory/ordinary-fellows/fellow/Professor-Eric-Aboagye-0008949.
- ↑ 4.0 4.1 4.2 "New AI is four times more accurate at predicting ovarian cancer deaths" (in en-GB). 2019-02-21. https://www.digitalhealth.net/2019/02/artificial-intelligence-ovarian-cancer-deaths/.
- ↑ "Eric Aboagye PhD FMedSci". https://www.fundacionareces.es/recursos/doc/portal/2019/01/29/eric-aboagye-eng.pdf.
- ↑ "Honours and Memberships - Professor Eric Aboagye". https://www.imperial.ac.uk/people/eric.aboagye/honours-and-memberships.html.
 |  |
